Announced
Completed
Financials
Tags
Domestic
United Kingdom
laboratory services
Majority
Acquisition
Private
Friendly
Completed
Biotechnology
Single Bidder
Private Equity
Synopsis
Phoenix Equity Partners-backed Sygnature Discovery, a drug discovery company, completed the acquisition of XenoGesis, the UK’s largest independent laboratory-based CRO. Financial terms were not disclosed. "This acquisition effectively doubles the size of our DMPK department (established in 2015), broadening our discovery and development expertise, complementing our existing service-offering and adding new skills and capabilities," Sygnature Discovery.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.